• In vitro Immunogenicity and Functional Testing of Nanoparticles, mRNA, and Biologics

      In a recent presentation during Oxford Global’s Biologics UK conference, Sofie Pattijn, site leader for ImmunXperts, a Q2 Solutions company, shared how in vitro bioassays provide a view of innate and early immune response.   Sofie highlighted several assays as examples to discuss the versatility and customization available to understand the immunologic mechanism of the […]

  • Happy to join the Nexelis family

    We are happy to announce that we will join the Nexelis family, and continue our growth with them. Looking forward to continue our collaboration and explore new opportunities together! Nexelis to Acquire Specialty Immunogenicity and Immune-Oncology Testing Laboratory ImmunXperts  

  • ImmunXperts Announces New Collaboration and Biowin Grant Award

    Gosselies, Belgium – October 24, 2016 — ImmunXperts S.A, together with Iteos Therapeutics S.A., ChemCom S.A., the de Duve Institute and IRIBHM have been awarded 1,6 million euro grant through a BioWin project called IT-Targets. The aim of this collaboration is to identify innovative drug candidates and biomarkers for immunotherapy of various types of cancer, […]

  • ImmunXperts to increase capital and appoint Thibault Jonckheere as CEO

    Gosselies, September 16th 2016 – ImmunXperts SA today announced that Thibault Jonckheere joined the fast growing company as CEO. Simultaneously, the immunogenicity company increased its capital to further accelerate the development of its immuno-oncology and cell therapy services. “ImmunXperts supports its partners in the evaluation of new drug candidates with a solid experimental platform for […]

  • ImmunXperts successfully raises in excess of 1 Million USD

    Gosselies, December 16th 2014 – ImmunXperts s.a. today announced it has successfully raised in excess of one million USD of seed financing. The proceeds will be used by the new start-up, located in the life science cluster of Gosselies Charleroi – Belgium, for the development of proprietary and innovative methods to assess the immunogenicity of […]